Case Series of People With HIV on the Long-Acting Combination of Lenacapavir and Cabotegravir: Call for a Trial.
Monica GandhiLucas HillJanet GrochowskiAlexander NelsonCatherine A KossFrancis Mayorga-MunozJon OskarssonMary ShielsAnn AveryLaura BamfordJillian BaronWilliam R ShortCorrilynn O HilemanPublished in: Open forum infectious diseases (2024)
In this case series of 34 patients on LEN/CAB, high rates of virologic suppression (94%) were observed. Reasons for using LEN/CAB included adherence challenges and underlying resistance, mostly to NNRTIs. These data support a clinical trial of LEN/CAB among persons with NNRTI resistance.
Keyphrases
- clinical trial
- antiretroviral therapy
- end stage renal disease
- hiv infected
- ejection fraction
- phase ii
- newly diagnosed
- study protocol
- chronic kidney disease
- phase iii
- hiv positive
- human immunodeficiency virus
- hepatitis c virus
- prognostic factors
- peritoneal dialysis
- randomized controlled trial
- open label
- hiv aids
- adipose tissue
- south africa
- artificial intelligence
- data analysis